Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Home - The Pharma Times | Pharma & Health Care News Portal
Thursday, April 25, 2024

Biotechnology

Pioneering Real World Study Reveals Successful Tele-ICU Collaboration for Remote Critical Care

BENGALURU, AUGUST 24,2023: In a recent publication that promises to reshape the landscape of healthcare accessibility, a research paper titled "A successful model of a Private-Public...

Apex Group of Hospitals Doctors use Botox treatment to restore Mumbai Falooda Seller voice...

Mumbai, August 22, 2023:  Mumbai- 40-year-old vendor from Bhayander by profession falooda seller Nishikanat Bhagwat (name changed)  was suffering from a voice problem from...

IT & Software Support

Appointments

Leena Srivastava appointed IIASA Deputy Director General for Science

Leena Srivastava appointed IIASA Deputy Director General for Science

New Delhi, August 29, 2019:The Vice Chancellor of the TERI School of Advanced Studies, New Delhi, Leena Srivastava will join the International Institute for...

Awards

ISF College of Pharmacy Organized Convocation-2021

* Degrees awarded to 250 students in the convocation, Moga New Delhi, January 8, 2022: Convocation-2021 of  ISF College of Pharmacy inaugurated Chief guest Dr....

Financial Results

Caredose registers 425% growth in the last quarter of FY 2018-19

To expand its services to five more cities apart from Delhi-NCR Targets expansion in...

Venus Remedies Net Profit Registers 51.88% Increase

The company’s net profit grew to Rs 40.49 crore in the nine-month period ending...

Approvals

Dr. Reddy’s Laboratories announces the launch of Ramelteon Tablets, in the U.S. Market

Hyderabad, July 23, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr....

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Bulk Drug

Health Care

Alternative Medicine

Eye Care

Dr. Basu Eye Hospital comes up with a free eye check-up camp at ...

New Delhi, September  20, 2023:  Dr. Basu Eye Hospital, a renowned name in the realm of Ayurvedic eye care, on the occasion of Prime...

Maxivision Eye Hospital Expands to 3 New Centers in Hyderabad, Extending Its Reach for...

Hyderabad, October 18, 2023: Maxivision Eye Hospital, one of the leading names in eye care networks in Telangana and beyond, is thrilled to announce...

Product News

Media Partners

Spotlight

Investments

Packaging

Latest News

Book ‘The Case Against IMA’ throws challenges at IMA: Dr Biswaroop Roy Chowdhury

New Delhi, December 02, 2021: Mounting a scathing attack on Indian Medical Association (IMA) for showing disdain for those practicing other medical systems and...

CORONA VACCINE: Who gets it first? Who pays?

By Dr. Sudhir Kumar, Apollo Hospitals, Jubilee Hills Most countries are involved in research into developing a vaccine against corona virus infection (causing COVID-19). The vaccine...

Dental Care

India’s leading dental chainoffers new year gift to crooked teeth patients – Clove InvisiBraces

Clove Dental has come up with special offers for its just launched invisible Aligners, a highly innovative alternative to existing metal braces  New Delhi, January...

Hospital Management

HCG Cancer Hospital completes Comprehensive Genomic Profi­ling (CGP) of 1000+ Cancer Patients

Bengaluru , August 22, 2023: Envisioned to drive a new standard of cancer care, Triesta Sciences, a Unit of HealthCare Global Enterprises Limited (HCG Cancer...

Drug Discovery & Development

Bharat Biotech and University of Maryland Accelerate Development of New Life Saving Conjugate Vaccine...

Receive USD 4 Million Award from The Wellcome Trust for Development and Clinical Trials Hyderabad, India, June 18, 2012: Bharat Biotech and The University of Maryland Center for  Vaccine Development (“CVD”) announced today a significant milestone achievement– receiving a USD  4 Million Strategic Translation Award from The Wellcome Trust for clinical development of a new  conjugate vaccine including initial clinical trials beginning in three years to prevent the potentially  lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS).   NTS have emerged as an important cause of invasive bloodstream infection in sub-Saharan Africa,  among young children with malaria and malnutrition, and among adults with HIV. Strains of nontyphoidal Salmonella (“NTS”) that can cause systemic disease such as meningitis or sepsis are  particularly common in sub-Saharan Africa; approximately 20 to 30% of children with such invasive  NTS infections die.

Suppliers

Technology

Companies

Jehan Impex becomes the first to introduce the future of swab...

New Delhi, October 01, 2020: India is recently holding the second position in terms of total number of cases of COVID-19. As the efforts...

Global Hearing Aid Market Outlook to 2023: Ken Research

Global Hearing Aid Market Outlook to 2023: Ken Research
New Delhi, August 31, 2019: The report Titled “Global Hearing Aid Market Outlook to 2023 - By Hearing Aid Devices (By Ear and By...

Marketing

Our Partners

Machinery & Equipments